MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external…
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external…
Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial assessing safusidenib in patients with chemotherapy-…
CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial.…
Actinium Pharmaceuticals has begun patient enrolment in its Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89 (RADIANZ) trial, an imaging…
Natera and Incyte have entered into a clinical collaboration agreement to conduct an interventional Phase II study of INCA33890 in…
Faeth Therapeutics’ cancer combination has improved outcomes in patients with advanced endometrial cancer in a Phase II trial – potentially…
Genmab’s petosemtamab, an investigational IgG1-bispecific antibody, plus Keytruda (pembrolizumab) reduced the risk of death by 50% in a Phase III…
This year's European Society of Medical Oncology (ESMO) Congress has come to a close, with hundreds of studies having been…
Since the Trump Administration took office in the White House, there has been an uptick in the number of guidance…
Arguably the most impactful readout in skin cancer in recent months was MSD and Moderna’s melanoma cancer vaccine data. At…